BioXcel Therapeutics, Inc. (BTAI) News
Filter BTAI News Items
BTAI News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
BTAI News Highlights
- BTAI's 30 day story count now stands at 7.
- Over the past 8 days, the trend for BTAI's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- The most mentioned tickers in articles about BTAI are III, AXSM and CONN.
Latest BTAI News From Around the Web
Below are the latest news stories about BIOXCEL THERAPEUTICS INC that investors may wish to consider to help them evaluate BTAI as an investment opportunity.
BioXcel Therapeutics Announces Positive Top-Line Data from Repeat Dosing of BXCL501 in Phase 1b Multiple Ascending Dose Trial in Healthy Volunteers for Major Depressive Disorder (MDD) ProgramBXCL501 was well tolerated across a broad dose range from 30mcg to 140mcg administered chronically Planning Phase 2 human proof-of-concept study to evaluate BXCL501 as a potential adjunctive treatment in MDD Data further supportive of ongoing clinical programs evaluating BXCL501 for potential at-home use for agitation associated with schizophrenia or bipolar disorders (SERENITY III) and agitation associated with Alzheimer’s disease (TRANQUILITY II and III) NEW HAVEN, Conn., May 16, 2023 (GLOBE N |
Why These 3 Nasdaq Stocks Were Glowing Green This WeekDespite another less-than-stellar Consumer Price Index report and more volatility among regional bank stocks, growth equities, on balance, were on the upswing this week. The tech-heavy Nasdaq Composite, for instance, edged higher by nearly 3% during the first three and a half days of trading this week, according to data provided by S&P Global Market Intelligence. Among the best performers within the growth stock landscape this week were biopharmaceuticals. |
BTAI: Three Data Readouts Expected in the Near Term…By David Bautz, PhD NASDAQ:BTAI READ THE FULL BTAI RESEARCH REPORT Business Update Data Readouts for Three Clinical Trials in Near Future BioXcel Therapeutics, Inc. (NASDAQ:BTAI) lead development compound, BXCL501, is currently being evaluated in multiple clinical trials. We anticipate important data readouts from three trials in the near term: • Topline data is anticipated in May 2023 from Part |
Q1 2023 BioXcel Therapeutics Inc Earnings CallQ1 2023 BioXcel Therapeutics Inc Earnings Call |
Why BioXcel Therapeutics Stock Marched Higher TodayThe biotech's Q1 earnings report set the stage for a flurry of important clinical updates in the coming months. |
Highly Rated Axsome Surges On Earnings Beat. And Here's Why BioXcel Reversed.Axsome and BioXcel issued divergent earnings reports Monday, but BTAI stock reversed an earlier dive and rose alongside AXSM stock. |
BioXcel Therapeutics Reports First Quarter 2023 Financial Results and Recent Operational HighlightsIGALMI™ (dexmedetomidine) commercial momentum accelerating with doubling of formulary wins, unlocking more than $55 million in targeted market opportunity, and an additional $255 million scheduled to vote Top-line data from pivotal SERENITY III Phase 3 trial (Part 1) for BXCL501 in bipolar or schizophrenia-associated agitation for at-home use expected in May 2023 Top-line data from repeat dosing of BXCL501 in Phase 1b trial for Major Depressive Disorder program in healthy volunteers expected in |
The Next Evolution In Drugs? It's Artificial Intelligence, Says This CEOBioXcel is banking on artificial intelligence to gain a second speedy FDA approval — and BTAI stock is soaring on the possibility. |
BioXcel Therapeutics to Present at the BofA Securities 2023 Health Care ConferenceNEW HAVEN, Conn., May 02, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics, will participate in a fireside chat at the BofA Securities 2023 Health Care Conference in Las Vegas on Tuesday, May 9, 2023 at 10:15 a.m. PT. He will be joined by Robert Risinger, M.D., Chie |
BioXcel Therapeutics to Report First Quarter 2023 Financial Results on May 8, 2023NEW HAVEN, Conn., April 24, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will release its first quarter 2023 financial results on Monday, May 8, 2023 before the open of the U.S. financial markets. BioXcel Therapeutics’ management team will also host a conference call and webcast at 8:00 AM ET that day to d |